INTRODUCTION
Dendritic cells (DCs) initiate adaptive immune responses by processing antigens and presenting them to T cells. 1 In the lung, the actions of DCs determine whether inhaled antigens elicit effector or tolerogenic immune responses. 2 DC migration from the lung to draining lymph nodes (LNs) proceeds at low levels during steady-state conditions, but the rate and volume of that migration is increased following exposure to pro-inflammatory stimuli. 3, 4 However, some antigen-bearing DCs remain in the lung for prolonged periods, [5] [6] [7] and selective depletion of DCs during the challenge phase of murine models of asthma abrogates allergic responses. 8, 9 These data suggest that DC retention in the lung might be important to activate memory T cells arriving in the lung. It is unknown, however, whether all DCs that are exposed to appropriate stimuli have the capacity to migrate to draining LNs. One possibility is that some lung DCs reside in an anatomical position that shields them from stimuli that would otherwise promote migration. Alternatively, DCs might become migratory on a stochastic basis that ensures an appropriate distribution of DCs in the lung and draining LNs. A third possibility is that some DCs lack the capacity for migration.
Recent studies have shown that pulmonary DCs are not homogeneous but are comprised of multiple subsets that can be distinguished phenotypically by their display levels of various cell surface markers. As in other non-lymphoid tissues, DCs in the lung are comprised of two major classical cDC subsets: CD11c high (hi) CD11b hi CD103 À DCs and CD11c hi CD11b low (lo) CD103 þ DCs, 10 often referred to as CD11b hi and CD103 þ DCs, respectively. CD103 þ DCs are tightly associated with the respiratory epithelium and extend processes into the lumen of the airway. 10 These cells represent the major DC subset in the lung for cross-presenting antigens to CD8 þ T cells, 11 promoting viral clearance 12 and directing T helper type 2 (Th2) responses to inhaled allergens. 13 CD11b hi DCs reside beneath the epithelium and can produce large amounts of chemokines.
14 In addition to CD11b hi DCs that are present in the lung during homeostasis, Ly-6C þ CD11c int CD11b hi monocyte-derived DCs (moDCs) are rapidly recruited to the lung during inflammation. 15 moDCs also display high levels of CD14, which distinguishes them from CD11b hi cDCs. 16 The migration of DCs to draining LNs is guided by interactions between the chemokine receptor, CCR7, and its ligands, CCL19 and CCL21, which are produced in the lymphatic vessels and in T-cell areas of LNs. [17] [18] [19] Many CD103
þ DCs display CCR7 and are dependent on this receptor for their migration to lung-draining mediastinal (m)LNs.
Consequently, CD103
þ DCs are virtually absent in mLNs of Ccr7 -/-mice. However, CD11b hi DCs can be found in mLNs of these mice, albeit at reduced levels compared with those of wildtype mice, 13, 20 suggesting that CD11b hi DCs can gain access to mLNs by both CCR7-dependent and -independent pathways. Other studies have confirmed that under some circumstances, CD11b
hi DCs can migrate from the lung to mLNs, 21, 22 but it is unclear whether all CD11b hi DCs have this potential. DCs are derived from monocytes and the common DC precursor (CDP). 23, 24 The latter can differentiate into either plasmacytoid DCs or pre-DCs 25, 26 . Recent studies have suggested that CD103 þ DCs are derived exclusively from CDPs and pre-DCs via a developmental pathway dependent on interactions between fms-like tyrosine kinase 3 (FLT3) and its ligand (FLT3L). 27, 28 However, CD11b hi DCs in mucosal tissue can develop from monocytes, which do not require FLT3 or FLT3L for their differentiation into DCs. 24 Blood-borne monocytes are comprised of two distinct populations, expressing high levels of the CCR2 and CX3CR1, respectively, 29 and both of these populations can give rise to lung DCs, even during homeostatic conditions. 30 Thus, the lung contains CDPderived classical CD103 þ and CD11b hi DCs (cDCs), as well as CD11b hi moDCs. Whether CD11b hi DCs in the lung that arise from these alternative developmental pathways possess different migratory capacities and functions is unknown. Here, we report that in the lung, FLT3-dependent CD103 þ cDCs and CD11b hi cDCs are migratory, whereas moDCs are non-migratory. These differences have important implications with regard to the initiation of primary T-cell responses in mLNs and stimulation of secondary T-cell responses in the lung.
RESULTS

CD103
þ DCs and a subpopulation of CD11b hi DCs are migratory DCs in the lung were identified as low-density CD11c þ I-A þ autofluorescence lo cells (see Supplementary Figure S1a online). Although alveolar macrophages are also CD11c þ , 31,32 their autofluorescence and display of Siglec-F distinguishes them from DCs (see Supplementary Figure S1b online). 33 Accordingly, we used autofluorescence to gate out macrophages from our analysis of pulmonary DCs. In mLNs, DCs were identified as CD11c
lo CD19 lo cells. We confirmed that CD11b hi DCs and CD103 þ DCs are the major DC subsets in the lungs of untreated mice, with CD103
þ DCs being slightly more abundant ( Figure 1a) . Under steady-state conditions, most DCs in lung-draining mLNs were CD11b hi , with very few CD103 þ DCs (Figure 1b ), in agreement with previous reports.
3
DC migration from the lung to mLNs is increased following inhalation of pro-inflammatory stimuli, such as lipopolysaccharide (LPS). 34 We found that the total number of CD11b hi DCs in the lung increased markedly during the 24-h period after instillation of ovalbumin (OVA) mixed with LPS (OVA/ LPS), whereas the number of CD103 þ DCs decreased (Figure 1a) , suggesting that some of the latter cells had migrated to mLNs. Analysis of mLNs revealed that both
CD11b
hi DCs and CD103 þ DCs were dramatically increased after OVA/LPS treatment ( Figure 1b) . The latter DC subset was increased 10-fold over the very low levels seen in mLNs of untreated mice.
Although DCs ferry antigen from peripheral tissue to draining LNs, some soluble proteins such as OVA can be carried rapidly in the lymph from the lung to mLNs, where they are taken up by mLN DCs. 20 Thus, in studies of lung DC migration, it is critically important to distinguish between antigen-bearing DCs arriving from the lung and mLN-resident DCs that acquire soluble antigens while in the LN. Previous studies have shown that inhaled carboxyfluorescein diacetate succinimidyl ester (CFSE) stains lung-resident DCs, thereby allowing these cells to be identified after their migration to mLNs. 20 However, instillation of CFSE causes airway inflammation, 35 which confounds studies of DC trafficking during homeostasis. For this reason, we tested the utility of an alternative fluorescent dye, PKH26 (PKH), 36 and found that it readily stained pulmonary DCs. No DCs in mLNs were stained by PKH by 4 h after PKH instillation, indicating that unlike OVA, PKH is not passively carried in the lymph to LNs. This allowed us to track the migration of PKH-stained pulmonary DCs to mLNs (Figure 1c Based on these results, we concluded that PKH was an appropriate dye to study pulmonary DC migration.
Instillation of OVA/LPS into the airway markedly increased the number of PKH þ DCs in mLNs compared with the number seen under steady-state conditions (Figures 1c,d) . The vast majority of these migratory DCs were CD103 þ , although some PKH þ CD11b hi DCs were also seen, and their numbers were also significantly increased by OVA/LPS. Most PKH þ DCs of both subsets displayed high levels of major histocompatibility complex (MHC) class II in agreement with a previous report showing that migratory DCs are MHC class II hi . 5 However, we found that some PKH þ CD11b hi DCs displayed moderate levels of this molecule (see Supplementary  Figure S1f online). Taken together, these data suggest that CD103 þ DCs are the major migratory DC subset in the lung, although a subpopulation of CD11b hi DCs also possesses migratory activity.
hi DC migration from the lung to mLNs is CCR7-dependent
CD103
þ DCs are virtually absent in mLNs of Ccr7 -/-mice, although some CD11b hi DCs can be found (Figure 1e) . 13, 20 This indicates that some CD11b hi DCs can gain access to mLNs by both CCR7-dependent and -independent pathways. To determine whether CD11b hi DCs can migrate from the lung to mLNs in a CCR7-independent manner, we used The relatively high migratory activity of CD103
þ DCs suggested that they might express higher levels of Ccr7 than do CD11b
hi DCs. To test this, we purified the two major lung DC subsets and prepared mRNA from them. CD103
þ DCs expressed more Ccr7 mRNA than did CD11b hi DCs (Figure 2a) . Instillation of LPS increased Ccr7 expression in both the DC subsets but much more strongly in CD103 þ DCs. This higher level of Ccr7 mRNA in CD103 þ DCs might have been due to a larger proportion of Ccr7-expressing cells or to more Ccr7 expression on a per cell basis. To distinguish between these possibilities, we attempted to estimate CCR7 display levels on individual cells by flow cytometry. Antibodies to CCR7 bound to this receptor on lung DCs and bone marrow-derived DCs (BMDCs) at 37 1C but not on ice (see Supplementary  Figures S2a,b online) . However, incubation of lung leukocytes at 37 1C altered the display of surface molecules, including MHC class II and CD115 (macrophage colony-stimulating factor receptor), on DCs and monocytes, respectively (see Supplementary Figures S2c,d online) . This precluded the simultaneous analysis of CCR7 together with certain other molecules. To circumvent this problem and to study Ccr7 expression under a variety of conditions without altering cellular phenotypes, we generated Ccr7 reporter mice in which the green fluorescent protein (GFP) coding region replaces that of Ccr7 (see Supplementary Figures S2f-i online) . These mice provided a rapid and temperature-independent method to study Ccr7 expression (see Supplementary Figure S2e online). On lung DCs, a much higher proportion of CD103
þ DCs expressed Ccr7-gfp than did CD11b hi DCs (Figure 2b ), in agreement with the migratory capacities of these two DC subsets. To determine whether the relatively small proportion of CD11b hi DCs expressing Ccr7 is an intrinsic property of these cells or simply due to their being shielded from LPS exposure in vivo, we purified GFP-negative CD11b hi and CD103 þ DCs from the lungs of Ccr7 gfp mice and stimulated the cells ex vivo with LPS. This treatment increased the proportion of Ccr7-gfpexpressing cells in both DC subsets but did so more effectively in CD103
þ DCs (Figure 2c ). This result indicates that the difference in Ccr7 expression between the two major lung DC subsets is likely due to intrinsic differences in their potential to express Ccr7 and not to their anatomical location in the lung.
We next analyzed DCs of mLNs in Ccr7 gfp mice. We found that a larger proportion of CD103
þ DCs expressed Ccr7-gfp than did CD11b hi DCs (Figure 2d ). However, when we restricted our analysis to PKH þ DCs that had migrated from the lung, the frequency of CCR7-GFP þ DCs was comparable between the CD11b hi and CD103 þ subsets. This finding is in agreement with the requirement of CCR7 for migration of CD103 þ and CD11b hi DCs to draining LNs ( Figure 1f ).
CD14
hi and Ly-6C hi CD11b hi DCs do not express Ccr7 or migrate to mLNs
To better characterize the migratory properties of CD11b hi DCs, we studied subpopulations of DCs in this subset. We first investigated inflammatory DCs, a subset of CD11b hi DCs that are derived from monocytes and are rapidly recruited to the airways by pro-inflammatory stimuli. 15 As remnants of their monocytic heritage, inflammatory moDCs express high levels of Ly-6C. 15, 37, 38 To determine whether these cells are migratory, we instilled LPS or polyinosinic-polycytidylic acid (poly (I:C)) into the airways of Ccr7 gfp mice. As expected, many CD103 þ DCs and a population of CD11b hi DCs that expressed high levels of MHC class II also expressed Ccr7-gfp ( Figure 3a) . However, Ly-6C hi CD11b hi inflammatory DCs expressed very low levels of Ccr7-gfp compared with Ly-6C lo CD11b hi DCs ( Figure 3b ). These data indicate that the Ly-6C hi inflammatory DCs that are rapidly recruited to the lung by pro-inflammatory stimuli do not express high levels of Ccr7.
In addition to inflammatory DCs, monocytes are reported to give rise to CD11b hi DCs that express high levels of the LPS coreceptor, CD14, even during steady-state conditions. 16, 29, 30 We found that Ccr7-gfp was expressed in CD11b hi DCs displaying intermediate or low levels of CD14 (CD14 med/lo ) DCs but not in CD14
hi DCs (Figure 3c ). Thus, neither Ly-6C hi inflammatory DCs nor CD14 hi CD11b hi DCs express high levels of Ccr7. The low expression of Ccr7 seen in CD14 hi CD11b hi DCs might have been due to a constraint imposed on them during their differentiation from monocytes. Alternatively, the anatomical location of these cells within the lung might have shielded them from signals that promote Ccr7 expression. To distinguish between these possibilities, we purified CCR7-GFPnegative DCs from the lungs of untreated Ccr7 gfp mice and fractionated the cells into three subsets: CD103 Figure 4d) . We next studied how the absence of inflammatory moDCs in Ccr2 -/-mice affected overall levels of Ccr7 expression in DCs. Wild-type and Ccr2 -/-mice were treated with LPS, and CD11b hi and CD103 þ DCs were purified by cell sorting. No differences in Ccr7 expression were seen for CD103
þ DCs, an expected result because these DCs are present at similar numbers in these two mouse strains. However, CD11b
hi DCs from Ccr2 -/-mice had much higher levels of Ccr7 than their counterparts in wild-type mice. This result is consistent with the low levels of Ccr7 expression in inflammatory DCs (Figure 3b ) and suggests that large number of inflammatory DCs in LPS-treated wild-type mice dilutes overall expression of this gene in CD11b hi DCs, whereas this effect is not seen in Ccr2 -/-mice because they lack inflammatory DCs (Figure 4e ). In agreement with this interpretation, we found that the number of migratory, PKH þ CD11b hi DCs was higher in mLNs of Ccr2 -/-mice than in wild-type mice (Figure 4f ). Taken together, these observations provide additional evidence that Ly-6C hi inflammatory DCs are non-migratory. À / À mice 24 h after LPS instillation (n ¼ 3). A representative result of two independent experiments is shown. GAPDH, glyceraldehyde 3-phosphate dehydrogenase; NS, not significant.
hi and Ly-6C hi CD11b hi DCs in the lung are non-migratory Our experiments thus far suggested that CD11b hi DCs in the lung are comprised of migratory CD14 med/lo DCs and nonmigratory Ly-6C hi inflammatory DCs and CD14 hi DCs. To confirm this, LPS instillation was used to recruit inflammatory DCs to the lung, and these cells, as well as the other DCs in the lung, were labeled by instillation of PKH (Figure 5a) . On the following day, the lungs and mLNs were excised and analyzed for the presence of PKH-labeled DCs. In the lung, the majority of PKH þ CD11b hi DCs were Ly-6C hi inflammatory DCs (Figure 5b, top) hi population in mLNs (Figure 5c ). Previous reports have shown that substantial numbers of Ly-6C hi inflammatory DCs are present in mLNs in the setting of acute inflammation, 37 although it has been unclear whether these cells emigrated from the lung. To test the possibility that a stronger pro-inflammatory stimulus is required to promote Ly-6C hi inflammatory DC migration to mLNs, we instilled 0.1 or 10 mg of LPS into the airways of mice. The recruited inflammatory DCs were subsequently labeled with PKH and their migration to mLNs assessed on the following day. The high-dose LPS led to a robust increase in total Ly-6C hi CD11b hi DCs in mLNs compared with treatment with the low-dose LPS (Figure 5d) . However, very few of these DCs were stained with PKH; almost all of the PKH þ CD11b hi DCs in the LN were Ly-6C lo (Figure 5e ). These results suggest that inflammatory DCs do not migrate from the lung to mLNs, even in the setting of acute inflammation.
The increase in non-migratory, Ly-6C hi DCs in mLNs of LPS-treated mice prompted us to investigate the origin of these cells. Ly-6C hi monocytes were prepared from BM, labeled with CFSE, and transferred into mice that had received instillations of either low-or high-dose LPS. In mice given low-dose LPS, relatively few CFSE-labeled Ly-6C hi monocytes were seen in mLNs. However, in mice given high-dose LPS, these cells were markedly increased (Figure 5f ). Together, these data suggest that the Ly-6C hi inflammatory DCs that accumulate in mLNs during acute inflammation are not migratory DCs arriving from the lung but are descendants of monocytes recruited directly from the blood to mLNs.
Our findings with moDCs in the lung were in apparent contrast to a previous report indicating CCR7-dependent accumulation of moDCs in skin-draining LNs. 16 In agreement with that study, we found that after systemic LPS injection into Ccr7 gfp mice, skin-draining LNs contained many Ccr7 gfpexpressing CD11b hi DCs, CD14 hi DCs, and CD103 þ DCs but no Ccr7 gfp -expressing Ly-6C hi inflammatory DCs (see Supplementary Figures S4a,b online) . We also confirmed that some in vitro generated moDCs also have the capacity to express Ccr7 (see Supplementary Figures S4c-e online) . Together, these data suggest that inflammatory DCs do not express Ccr7, but its expression in CD14
hi DCs is tissuedependent.
Ly-6C
hi and CD14 hi DCs are monocyte-derived and develop independently of FLT3L
We next investigated whether the diverse migratory potential of the various CD11b hi DC subpopulations in the lung was related to their developmental pathways. We reasoned that Flt3L -/-mice would be useful in this regard because these mice lack CDPs, 25, 26, 40 which can differentiate into cDCs 25, 26 but not monocytes. Flt3L -/-mice also lack CD103 þ DCs, 27 a finding that we confirmed for untreated and OVA/LPS-treated mice (Figure 6a) Figures S5a, b and Supplementary Methods online) from the BM of CD45.1 mice and adoptively transferred these cells to CD45.2-recipient mice, whose airways had been instilled with OVA/LPS before the monocyte transfer. By gating on CD45.1 þ I-A þ CD11c þ cells, we were able to follow the fate of moDCs in the lung (Figure 6c) . At one day post-transfer, almost all of these cells were Ly-6C hi inflammatory DCs. Over time, the total number of donor moDCs in the lung declined, and CD14
hi DCs became dominant population (Figures 6c,d) hi DCs (Figure 6b) . The latter appeared to be mature, as judged by their high levels of CD86 and I-A (see Supplementary Figure S5c 16, 37, 38 Th2 induction by total DCs prepared from Flt3L -/-mice was impaired, likely because they lack CD103
þ DCs, which efficiently prime Th2 differentiation. 13 Thus, based on their expression of MHC class II, DC-like morphology, and T-cell-stimulating capability, we concluded that CD14
hi CD11b hi cells in the Flt3L -/-mouse lungs are likely functional moDCs, and that Flt3L -/-mice are a useful genetic model for studying migratory and functional properties of moDCs in vivo.
Having confirmed that the CD11b
hi DCs in Flt3L -/-mice are restricted to moDCs, we investigated Ccr7 expression in lung DCs in these animals. CD11b
hi DCs from Flt3L -/-mice did not express appreciable levels of Ccr7 mRNA (Figure 7a) .
Moreover, whereas PKH-labeled CD11b
hi DCs from wildtype mice readily migrated to mLNs, CD11b hi DCs counterparts from Flt3L -/-mice did not, even when low-(0.1 mg) or high-dose (10 mg) LPS (Figures 7b,c) was instilled to induce inflammation. The virtual absence of PKH þ migratory CD11b hi DCs in mLNs of Flt3L -/-mice was probably not related to unanticipated changes in the lymphatics or the LNs of these animals, because in vitro-generated wild-type BMDCs migrated from the airway to mLNs of Flt3L -/-and wild-typerecipient mice with comparable efficiencies (Figure 7d) . To confirm that FLT3/FLT3L interactions are required for the development of migratory DCs, we tested lung DC migration in chimeric mice in which wild-type mice received a mixture of BM from genetically marked wild-type (CD45.2) and Flt3 -/-donor (CD45.1) mice. PKH was instilled into the airways of these chimeric mice so that we could follow migration of both types of donor-derived DCs to mLNs. As expected, PKH þ
CD103
þ DCs in the lung and LNs of these chimeric mice were derived exclusively from wild-type (CD45.2) mice because FLT3 is required for the development of these cells (Figures 7e-g ). By contrast, PKH þ CD11b hi DCs in the lungs of the chimeric mice were derived almost equally from wild-type and Flt3 -/-donors. Despite that, almost all PKH þ CD11b hi DCs in mLNs of the chimeric mice were derived from wild-type donors. Thus, although Flt3 -/-CD11b hi moDCs develop normally and accumulate in the lung, they do not readily migrate to mLNs. Based on these results, we conclude that in the lung, migratory DCs are comprised almost exclusively of FLT3-and FLT3L-dependent cDCs, and that FLT3-and FLT3L-independent moDCs are intrinsically non-migratory. 
DISCUSSION
Lung-resident DCs are well-known to take up inhaled antigens and migrate to draining LNs for presentation of antigenderived peptides to naive T cells. However, in experimental models of asthma DCs are also required during the challenge phase, 8, 9 suggesting that some DCs have evolved to remain in the lung and activate antigen-specific memory cells recruited to the lung upon secondary exposure to antigens. For example, lung-resident DCs are required to trigger release of inflammatory mediators by influenza-specific CD8 þ T cells during the late phase of influenza infection, after most of the virus has been cleared. 41 Thus, non-migratory, lung-resident DCs might provide important functions during recall responses to antigen challenge. If so, reducing or preventing the accumulation of these cells in the inflamed lung might diminish the pathological inflammation seen in these and other diseases.
It has been unclear whether the migration of individual DCs is stochastic, determined solely by exposure to pro-inflammatory stimuli or cytokines, or whether some DCs are programmed to remain in the lung. Resolving this issue should provide important clues to the primary functions of DC subsets. Our present findings reveal that in the lung, most cDCs, including CD103
þ DCs and the CD14 med/lo subset of CD11b hi DCs, are capable of expressing Ccr7 and migrating from the lung to mLNs, whereas moDCs do not express this receptor and do not migrate to draining LNs. We found that compared with lung-resident CD103 þ DCs, fewer CD11b
hi DCs expressed Ccr7 after stimulation with LPS in vivo. This difference was largely due to the virtual absence of Ccr7 expression on the monocyte-derived subset of CD11b hi DCs. In fact, CD14
hi moDCs failed to express Ccr7, even after their purification from the lung and culture with LPScontaining media, whereas Ccr7 was strongly increased under these conditions in CD14 med/lo CD11b hi cDCs and in CD103 þ cDCs. This finding argues against the hypothesis that the inability of CD14 hi moDCs to increase Ccr7 expression is due solely to their anatomical positioning within the lung. Rather, our data suggest that the migratory properties of lung DCs are intrinsically programmed. Not all CD11b hi cDCs and CD103 þ cDCs were CCR7-GFP þ after their overnight culture with LPScontaining media, but it is likely that Ccr7 expression had declined in some cells by the end of the culture period. This idea is supported by our finding that only half of PKH þ migratory DCs in draining LNs were CCR7-GFP þ , even though the migration of these cells is critically dependent on CCR7 and occurred during the 24 h between the labeling of these cells in the lung and their analysis in the LN. Thus, Ccr7 might be expressed only long enough to allow DC migration from the lung to T-cell zones in draining LNs.
Our present data suggest that the absence of Ccr7 expression in moDCs was not due solely to a lack of maturity because this receptor was absent not only in inflammatory DCs, but also in CD14 hi
CD11b
hi DCs in wild-type mice during steady-state conditions and in all CD11b hi moDCs from Flt3L -/-mice. Apart from their levels of Ccr7 expression, the latter DCs appeared fully mature, as determined by their high display levels of MHC class II and co-stimulatory molecules, their DClike morphologies, and their ability to stimulate naive T-cell differentiation. Therefore, the absence of Ccr7 expression in moDCs is likely an intrinsic property of these cells and related to their descent from monocytes. The migratory differences between CD11b hi moDCs and CD11b hi cDCs might help to reconcile previous reports that came to different conclusions regarding the migratory properties of pulmonary CD11b hi DCs. 3, 20, 21, 42, 43 Although the signaling pathways that control Ccr7 expression are not yet well understood, a comparison of the transcriptional and epigenomic status of CD11b hi cDCs and moDCs will likely be informative in this regard.
Our finding that moDCs in the lung lack Ccr7 expression and are non-migratory is in apparent contrast with previous reports showing that moDCs can accumulate in LNs in a CCR7-dependent manner upon systemic administration of LPS 16 and that Ccr7 is expressed on Langerhans cells, 44 which are monocyte-derived. 45 We also confirmed that BM monocytes can differentiate into Ccr7-expressing DCs. Thus, not all moDCs lack Ccr7. It is possible that the microenvironment of the lung-and perhaps other tissues-provide signals that suppress Ccr7 expression in moDCs. Although in most cases the identities of such putative signals are unknown, there are several precedents for phenotypic differences among DCs of different tissues. For example, Langerhans cells are present only in the skin, and CD103 þ CD11b þ double-positive cells are found in large numbers in the lamina propria of the gut but are rare in the lung. 13, 28 Interestingly, these double-positive cells, which are CX3CR1 À , express Ccr7 and migrate to gut-draining LNs, whereas CD103 À CX3CR1 þ DCs in the lamina propria are non-migratory. 28, 46 To date, there have been no reports of CD103 À CD11b hi migratory cDCs in the gut that are similar to those that we have found in the lung. It is possible that the CD11b þ CD103 þ double-positive DCs in the gut are functionally analogous to CD14 med/lo CD11b hi cDCs in the lung, and that the phenotypic differences between these DC populations result from distinct signals provided by the different microenvironments in those organs. These observations imply that phenotypes of DCs are largely, but not entirely, determined during lineage differentiation. Identification of molecular signals in non-lymphoid tissue that act to fine tune functions of DCs will likely be an important area of future research in DC biology.
METHODS
Mice. C57BL/6, Ccr7 -/-, CD45.1 and OT-II TCR transgenic mice were purchased from Jackson Laboratories (Bar Harbor, ME). Flt3L -/-mice and control C57BL/6 mice were from Taconic (Germantown, NY). Ccr7 gfp and Ccr2 À / À targeted insertion reporter mice on a C57BL/6 background were generated at Xenogen (Caliper Life Sciences, Hopkinton, MA) through a contractual arrangement with the NIEHS (see Supplementary Figures S2 and S3 online) . Flt3 À / À mice originally generated by Ihor Lemischka (Mount Sinai School of Medicine) were provided by Michel Nussenzweig (Rockefeller University). Mice were housed in specific pathogen-free conditions at the NIEHS or Rockefeller University and used between 6 and 12 weeks of age in accordance with guidelines provided by the Institutional Animal Care and Use Committees.
Mouse sensitization and cell-tracker administration. Mice were anesthetized by isoflurane inhalation and given 100 mg endotoxin-free OVA (Profos AG, Germany), alone or together with 0.1 mg LPS (Sigma, St Louis, MO) or with 1 mg poly (I:C) (InvivoGen, San Diego, CA) unless otherwise specified. Instillations of reagents were done by oropharyngeal aspiration as described previously. 47 In some experiments, DCs were labeled in vivo by instillations of 50 ml of 10 mm PKH26 (Sigma) or CFSE (Invitrogen, Grand Island, NY) 24 h before OVA/LPS instillation unless specified. OVA-bearing DCs were identified by instillation of endotoxin-free OVA labeled with Alexa Fluor 647 (Invitrogen). For skin-draining DC analysis, 200 ml phosphate-buffered saline containing 0.1 mg LPS was injected into mouse tail veins 24 h before tissue harvest. To examine cell-tracker dye-induced airway inflammation, bronchoalveolar lavage was performed on mice 24 h after instillation of cell trackers, and the cells were counted under a microscope.
Preparation and analysis of pulmonary DCs. DCs from the mouse lungs and mLNs were prepared as described previously. 13 Cells were diluted to 2 Â 10 6 /100 ml and incubated with a non-specific-binding blocking reagent cocktail of anti-mouse CD16/CD32 (2.4G2), normal mouse, and rat serum (Jackson ImmunoResearch, West Grove, PA) for 5 min. For staining of surface antigens, cells were incubated with fluorochrome (Allophycocyanin (APC), APC-Cy7, Alexa Fluor 488, Alexa Fluor 647, eFluor 450, eFluor 605 NC, FITC, PerCP-Cy5.5 or Phycoerythrin), or biotin-conjugated antibodies against mouse CD3e (145-2C11), CD11b (M1/70), CD11c (N418 and HL3), CD14 (Sa2-8), CD19 (6D5), CD45.1 (A20), CD86 (GL1), CD103 (M290), CD115 (AFS98), CD117/c-Kit (2B8), CD197/CCR7 (4B12), Ly-6C (AL-21), Ly-6G (1A8), MHC class II I-A b (AFb.120), MMR (MR5D3) and Siglec-F (BD Biosciences (San Jose, CA), BioLegend (San Diego, CA) and eBioscience (San Diego, CA)). Staining with biotinylated antibodies was followed by fluorochrome-conjugated streptavidin. Stained cells were analyzed on a 5 laser LSRII, or sorted on a 5 laser ARIA-II flow cytometer (BD Biosciences), and the data analyzed using FACS Diva (BD Bioscience) and FlowJo software (Treestar, Ashland, OR). Dead cells were excluded based on their forward and side scatter. Only single cells were analyzed. In some experiments, DC subsets were purified and cultured in complete RPMI1640 (cRPMI) containing 100 ng ml À 1 LPS (Sigma), in addition to 10% fetal bovine serum (Gemini, West Sacramento, CA), penicillin/streptomycin (InvitroGen) and 50 ng ml À 1 b-mercaptoethanol (Sigma). In some experiments, cells from purified subsets were centrifuged onto glass slides and photographed using an Olympus BX51 microscope, DP70 digital camera, and DP software (Olympus, Center Valley, PA).
Purification of monocytes and in vitro generation of DCs.
Inflammatory monocytes (CD3
hi Ly-6G À TER119 À 7-AAD À ) from BM were enriched using an automated magnet-activated cell sorter (Miltenyi, Auburn, CA) and then further purified by flow cytometry-based sorting. To prepare BMDCs, marrow was collected, RBCs lysed with 0.15 M ammonium chloride and 1 mM potassium bicarbonate, and the cells cultured in cRPMI containing 5 ng ml À 1 GM-CSF (granulocyte macrophage colony-stimulating factor; R&D Systems) for 9 days. To generate moDCs in vitro, purified BM monocytes were cultured in cRPMI containing 5 ng ml À 1 GM-CSF and IL-4 (R&D Systems). After 4 or 7 days of culture, cells were harvested and analyzed by flow cytometry or microscopy as described above.
BM chimera mice. BM chimeric mice were generated using a mixture of BM cells from C57BL/6 (CD45.2) and Flt3 À / À (CD45.1) mice at 4:6 ratio that was intravenously injected into tail veins of 9 Gy g-rayirradiated C57BL/6 mice (10 7 cells/recipient) 6 weeks before experiment. 16 Adoptive transfer of cells. For BMDC migration assays, 10 6
CD11c
þ I-A þ DCs from CD45.1 þ mice were instilled into airways of recipient CD45.2 þ mice, and the efficiency of migration to mLNs assessed by quantitation of CD45.1 þ donor DCs in mLNs. For monocyte fate studies, 6 Â 10 5 purified monocytes were intravenously injected into mouse tail veins.
Co-culture of naive T cells with DCs. Naive CD4 þ T cells were prepared from pools of LNs and spleens of OT-II TCR transgenic mice as previously described. 13 DCs were purified by flow cytometric sorting 13 from the lungs of mice that had received OVA/LPS 16 h earlier. The OT-II T cells (10 5 /well) were cultured together with lung DCs (5 Â 10 4 /well) in a 5% CO 2 incubator in 200 ml Iscove's modified Dulbecco's medium containing 10% fetal bovine serum (certified, Invitrogen), 50 mM b-mercaptoethanol, penicillin, and streptomycin in a 96-well U-bottom plate (BD Biosciences). After 5 days of the primary co-culture, T cells (10 
